ATE449847T1 - Hepatitis c rezeptorprotein cd81 - Google Patents

Hepatitis c rezeptorprotein cd81

Info

Publication number
ATE449847T1
ATE449847T1 AT98946642T AT98946642T ATE449847T1 AT E449847 T1 ATE449847 T1 AT E449847T1 AT 98946642 T AT98946642 T AT 98946642T AT 98946642 T AT98946642 T AT 98946642T AT E449847 T1 ATE449847 T1 AT E449847T1
Authority
AT
Austria
Prior art keywords
hepatitis
receptor protein
protein
diagnosis
therapy
Prior art date
Application number
AT98946642T
Other languages
English (en)
Inventor
Sergio Abrignani
Guido Grandi
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9721182.5A external-priority patent/GB9721182D0/en
Priority claimed from GBGB9813560.1A external-priority patent/GB9813560D0/en
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE449847T1 publication Critical patent/ATE449847T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98946642T 1997-10-06 1998-10-06 Hepatitis c rezeptorprotein cd81 ATE449847T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9721182.5A GB9721182D0 (en) 1997-10-06 1997-10-06 Hepatitis C receptor protein
GBGB9813560.1A GB9813560D0 (en) 1998-06-23 1998-06-23 Hepatitis C Receptor Protein
PCT/IB1998/001628 WO1999018198A1 (en) 1997-10-06 1998-10-06 Hepatitis c receptor protein cd81

Publications (1)

Publication Number Publication Date
ATE449847T1 true ATE449847T1 (de) 2009-12-15

Family

ID=26312375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98946642T ATE449847T1 (de) 1997-10-06 1998-10-06 Hepatitis c rezeptorprotein cd81

Country Status (12)

Country Link
US (4) US7097987B2 (de)
EP (1) EP1021534B1 (de)
JP (3) JP4198882B2 (de)
AT (1) ATE449847T1 (de)
AU (1) AU9363398A (de)
CA (1) CA2304796C (de)
CY (1) CY1109868T1 (de)
DE (1) DE69841322D1 (de)
DK (1) DK1021534T3 (de)
ES (1) ES2334727T3 (de)
PT (1) PT1021534E (de)
WO (1) WO1999018198A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113914A1 (en) * 2001-12-10 2003-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of CD81 expression
US20020160936A1 (en) * 1999-09-29 2002-10-31 Howard J. Worman Hcv e2 protein binding agents for treatment of hepatitis c virus infection
GB9927320D0 (en) * 1999-11-18 2000-01-12 Chiron Spa Exosome separation
EP1245236A4 (de) * 1999-12-28 2004-09-22 Sumitomo Pharma Prophylaktika und therapeutika zur behandung von chronischer hepatitis
US7101551B2 (en) 2000-02-14 2006-09-05 Mitsubishi Pharma Corporation Remedies for hepatitis C
JP2001299140A (ja) * 2000-04-24 2001-10-30 Sumitomo Pharmaceut Co Ltd Ｈｃｖを増幅しうる細胞及び非ヒト動物
GB0016361D0 (en) * 2000-07-03 2000-08-23 Chiron Spa Structure-based HCV drug design
US8039602B2 (en) 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
WO2003014728A1 (fr) * 2001-08-10 2003-02-20 Mitsubishi Pharma Corporation Medicaments contre l'hepatite c
EP1662007B9 (de) * 2003-08-28 2012-02-29 Dainippon Sumitomo Pharma Co., Ltd. Mittel zur vorbeugung oder heilung entzündlicher darmerkrankungen mit anti-cd81-antikörper als aktivem inhaltsstoff
US20070266448A1 (en) * 2006-05-11 2007-11-15 Alexander Lifke Method for the production of antibodies
NL2001318C2 (nl) 2008-02-25 2009-08-26 Schuitemaker Mach Bv Inrichting en werkwijze voor het snijden van kuilvoer.
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
KR20140107615A (ko) * 2011-12-26 2014-09-04 시오노기 앤드 컴파니, 리미티드 엑소좀 검출용 모노클로날 항체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500880A (ja) 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
US5631407A (en) * 1989-03-10 1997-05-20 The Trustees Of Columbia University In The City Of New York Transgenic mouse expressing DNA sequences encoding the human poliovirus receptor
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
WO1991007489A1 (en) * 1989-11-22 1991-05-30 Childrens Hospital Of Los Angeles Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
GB9517926D0 (en) 1995-09-01 1995-11-01 Biocine Spa Binding protein
US6031088A (en) * 1996-05-23 2000-02-29 Albert Einstein College Of Medicine Of Yeshiva University Polycystic kidney disease PKD2 gene and uses thereof
US7491865B2 (en) * 2004-08-19 2009-02-17 Fred Hutchinson Cancer Research Center Mouse models of prostate cancer development and metastasis through expression of a hepsin transgene

Also Published As

Publication number Publication date
US20070087407A1 (en) 2007-04-19
CA2304796A1 (en) 1999-04-15
US20090025098A1 (en) 2009-01-22
CA2304796C (en) 2013-12-03
US7097987B2 (en) 2006-08-29
US20120066779A1 (en) 2012-03-15
PT1021534E (pt) 2010-03-03
AU9363398A (en) 1999-04-27
JP4198882B2 (ja) 2008-12-17
EP1021534A1 (de) 2000-07-26
CY1109868T1 (el) 2014-09-10
JP2001519150A (ja) 2001-10-23
DE69841322D1 (de) 2010-01-07
JP2009035553A (ja) 2009-02-19
WO1999018198A1 (en) 1999-04-15
US20040258694A1 (en) 2004-12-23
ES2334727T3 (es) 2010-03-15
HK1025793A1 (en) 2000-11-24
EP1021534B1 (de) 2009-11-25
DK1021534T3 (da) 2010-02-01
JP2012125246A (ja) 2012-07-05

Similar Documents

Publication Publication Date Title
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EP1409544A4 (de) Humane dr4-antikörper und deren anwendungen
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
EP1539228A4 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
TR200000913T2 (tr) Tıbbi maddeler
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
EP1178988A4 (de) Verbindungen und therapeutische methoden
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
EP1532162A4 (de) Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
NO986218L (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1021534

Country of ref document: EP